- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Geen informatie over farmacokinetische parameters bij kinderen beschikbaar .
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
Off-label
Licensed use Licensed useA second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
Tablet 150 mg
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Adult Side Effects
Bij therapie in combinatie met atazanavir: Zeer vaak (> 10%): misselijkheid. Geelzucht.
Vaak (1–10%): droge mond, braken, dyspepsie, buikpijn, flatulentie, diarree. Toegenomen eetlust, hyperglykemie. Hyperbilirubinemie. Hoofdpijn, duizeligheid, slaperigheid, slapeloosheid, vermoeidheid, ongewone dromen, dysgeusie. Huiduitslag.
Soms (0,1–1%): koorts, asthenie. Depressie. Proteïnurie, hematurie, nefrolithiase. Myalgie. Jeuk.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Antidotes | ||
|---|---|---|
| V03AB27 | ||
| V03AB16 | ||
| V03AB24 | ||
| V03AB25 | ||
| V03AB33 | ||
| V03AB17 | ||
| V03AB15 | ||
| V03AB13 | ||
| V03AB19 | ||
| V03AB14 | ||
| V03AB06 | ||
| V03AB35 | ||
| Iron chelating agents | ||
|---|---|---|
| V03AC03 | ||
| V03AC02 | ||
| V03AC01 | ||
| Drugs for treatment of hyperkalemia and hyperphosphatemia | ||
|---|---|---|
| V03AE07 | ||
| V03AE01 | ||
| V03AE02 | ||
| V03AE01 | ||
| Detoxifying agents for antineoplastic treatment | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| Drugs for treatment of hypoglycemia | ||
|---|---|---|
| V03AH01 | ||
| DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children., Guideline for the use of Antiretroviral agents in pediatric HIV infection, www.aidsinfo.nig.gov/contentfiles/lvguidelines/pediatricguidelines, Geraadpleegd 14 feb 2017
- Bamford, A., et al (PENTA Steering Committee) (2015), Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. , HIV Med, 2015, doi:10.1111/hiv.12217
- Bamford, A., et al (PENTA Steering Committee) (2015), Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life., HIV Med, 2015, doi:10.1111/hiv.12217
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
